HeimNOVN • SWX
add
Novartis AG
Við síðustu lokun
91,56 CHF
Dagbil
92,04 CHF - 93,99 CHF
Árabil
83,63 CHF - 102,72 CHF
Markaðsvirði
205,76 ma. CHF
Meðalmagn
2,97 m.
V/H-hlutf.
12,39
A/V-hlutfall
3,52%
Aðalkauphöll
SWX
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 13,17 ma. | 8,93% |
Rekstrarkostnaður | 5,52 ma. | -24,45% |
Nettótekjur | 3,19 ma. | 81,09% |
Hagnaðarhlutfall | 24,21 | 66,28% |
Hagnaður á hvern hlut | 2,06 | 18,39% |
EBITDA | 5,50 ma. | 88,62% |
Virkt skatthlutfall | 5,91% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 13,85 ma. | 8,08% |
Heildareignir | 103,52 ma. | -8,14% |
Heildarskuldir | 60,08 ma. | -19,30% |
Eigið fé alls | 43,44 ma. | — |
Útistandandi hlutabréf | 2,00 ma. | — |
Eiginfjárgengi | 4,23 | — |
Arðsemi eigna | 10,97% | — |
Ávöxtun eigin fjár | 15,05% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 3,19 ma. | 81,09% |
Handbært fé frá rekstri | 6,29 ma. | 16,88% |
Reiðufé frá fjárfestingum | -374,00 m. | 83,09% |
Reiðufé frá fjármögnun | -382,00 m. | 54,09% |
Breyting á handbæru fé | 5,71 ma. | 275,39% |
Frjálst peningaflæði | 4,55 ma. | -63,57% |
Um
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Framkvæmdastjóri
Stofnsett
29. feb. 1996
Höfuðstöðvar
Vefsvæði
Starfsfólk
76.057